SGLT2 inhibitors beyond diabetes: the honest heart and kidney evidence behind Jardiance and Farxiga

What SGLT2 inhibitors actually are

SGLT2 stands for sodium-glucose cotransporter-2 — a protein in the kidney that does something you might not expect the body to bother doing: it reclaims glucose from your urine and puts it back into your blood. SGLT2 inhibitors, sometimes nicknamed “gliflozins” after their shared drug-name ending, block that reclamation. The result is that you excrete a meaningful amount of sugar in your urine every day, which is why they were developed as diabetes drugs in the first place.

The class is a handful of once-daily oral tablets. The two with the deepest outcomes evidence are empagliflozin (brand name Jardiance) and dapagliflozin (Farxiga); canagliflozin (Invokana) and ertugliflozin (Steglatro) round out the group. They are pills, not injections, which matters for adherence in the chronic conditions they treat. And here is the twist that makes this whole article necessary: the blood-sugar lowering, the thing they were built to do, turned out to be almost the least interesting thing about them. The story that rewrote guidelines is what happened to hearts and kidneys — frequently in people whose blood sugar was never the problem.

The mechanism: glucose in the urine, and then some

Follow the sugar and you see the first-order effect. In the kidney’s filtering tubules, the SGLT2 protein normally grabs filtered glucose and pulls it back into the bloodstream so you don’t waste it. Block SGLT2 and that glucose stays in the urine and leaves the body — a phenomenon called glucosuria (sugar in the urine). Lose glucose in the urine and blood sugar falls modestly. Straightforward enough, and if that were the whole story these would be unremarkable diabetes drugs.

But excreting glucose drags other things along with it, and this is where the cardiorenal benefits are thought to originate. Because glucose is osmotically active, dumping it in the urine also pulls out sodium and water — a gentle, sustained diuretic and natriuretic effect that lowers blood pressure and reduces the volume the failing heart has to move. That hemodynamic offloading is one leading explanation for the heart-failure benefit. In the kidney, SGLT2 inhibition changes the pressure inside the glomerulus (the filtering unit), easing the intraglomerular hypertension that drives kidney disease forward — a mechanism analogous to how ACE inhibitors protect kidneys. Layered on top are metabolic shifts (a nudge toward ketone-based fuel that may make the heart more efficient), reduced inflammation and fibrosis, and lower sympathetic-nervous-system activation.⁶

The honest framing: the outcomes are settled, but the exact mechanism is not. The JACC state-of-the-art review by Zelniker and Braunwald lays out a menu of plausible, overlapping pathways — hemodynamic, metabolic, anti-inflammatory — without a single decisive winner.⁶ That is why the mechanism claim earns an EMERGING grade even though the clinical benefits are STRONG. We know these drugs work; we are still arguing about precisely why.

They were built to lower blood sugar by wasting it in the urine. The thing that made them famous is what happened downstream — to the heart and the kidney, in people whose sugar was fine.

EMPA-REG OUTCOME: the surprise that started it

The modern SGLT2 story begins in 2015 with EMPA-REG OUTCOME. Like other diabetes drugs of the era, empagliflozin had to prove it didn’t increase cardiovascular risk — a safety exercise regulators required after older glucose drugs disappointed. It cleared that bar and then blew past it. In more than 7,000 patients with type 2 diabetes (T2D) and established cardiovascular disease, empagliflozin cut the primary composite of cardiovascular (CV) death, nonfatal heart attack, and nonfatal stroke — a bundle known as MACE (major adverse cardiovascular events). More striking was the CV-death component, reduced by roughly a third in relative terms, along with a large drop in hospitalization for heart failure.¹

That was the electric moment: a diabetes pill lowering cardiovascular death, and doing it fast — the curves separated within months, too quickly to be explained by atherosclerosis reversal. But keep the framing honest. EMPA-REG enrolled a high-risk population — diabetics who already had heart disease — so the impressive relative risk reduction (RRR) sits on top of a high baseline risk. A one-third relative cut in CV death is a lot when the underlying risk is high; it would mean far less in a healthy 45-year-old. And it was a single trial of one drug in one population. That is exactly why the CV-death and MACE claim earns a MODERATE grade rather than STRONG: real, important, replicated in spirit by the heart-failure and kidney trials — but the headline mortality finding is anchored to a specific, high-risk diabetic group, not a universal promise.

Heart failure: the most consistent finding in the class

If EMPA-REG was the spark, heart failure is where the fire caught — and it is the single most robust, best-replicated benefit of the whole class. The reason it earns a STRONG grade is consistency: the same result appeared with two different drugs, across the entire range of heart function, in patients with and without diabetes.

First, a quick vocabulary check. Heart failure (HF) is usually split by ejection fraction (EF) — the percentage of blood the left ventricle pumps out with each beat. HFrEF is heart failure with reduced ejection fraction (a weak pump); HFpEF is heart failure with preserved ejection fraction (the pump squeezes normally but the heart is stiff and doesn’t fill well). HFpEF had been a graveyard for drug trials — almost nothing worked — which makes what follows notable.

DAPA-HF (2019) randomized 4,744 patients with HFrEF to dapagliflozin or placebo on top of standard therapy. Dapagliflozin cut the primary composite of worsening heart failure or cardiovascular death, and — crucially — the benefit held whether or not the patient had diabetes.² EMPEROR-Reduced (2020) reproduced the finding with empagliflozin in HFrEF, cutting the composite of CV death or HF hospitalization by about 25 percent (hazard ratio 0.75).⁵ A hazard ratio (HR) below 1 means fewer events in the treated group; 0.75 means a 25 percent relative reduction.

Then the wall fell. EMPEROR-Preserved (2021) tested empagliflozin in nearly 6,000 patients with HFpEF — the population nothing had helped — and cut the composite of CV death or HF hospitalization by 21 percent (HR 0.79), driven mainly by fewer hospitalizations.³ It was the first clearly positive trial in preserved-EF heart failure in a generation. Taken together, HFrEF and HFpEF, dapagliflozin and empagliflozin, diabetic and non-diabetic: the message is the same. That convergence is what makes the heart-failure claim as solid as anything in the field.

The kidney: slowing decline, even without diabetes

The third pillar is the kidney, and it carries the same headline that makes this class remarkable: the benefit is not limited to diabetics. Chronic kidney disease (CKD) is the slow, often silent loss of the kidney’s filtering capacity, and its endgame — dialysis or transplant — is one of medicine’s heaviest burdens. Slowing that trajectory is a big deal.

DAPA-CKD (2020) randomized 4,304 patients with chronic kidney disease — with and without type 2 diabetes — to dapagliflozin or placebo on top of standard ACE-inhibitor or ARB therapy. Dapagliflozin significantly reduced the composite of a sustained 50 percent drop in kidney filtration, progression to end-stage kidney disease, or death from kidney or cardiovascular causes.⁴ The trial was actually stopped early for overwhelming benefit. And the effect was consistent in the non-diabetic subgroup — the clearest demonstration yet that SGLT2 inhibition protects kidneys through a mechanism that isn’t just about controlling blood sugar. Crucially, this was not a one-trial finding: EMPA-KIDNEY (2023) replicated it with empagliflozin in a broad CKD population that was roughly 57 percent non-diabetic, again slowing progression toward kidney failure.⁸ Two large trials, two drugs, a majority-non-diabetic signal in the second — that replication is why the kidney claim earns a STRONG grade, and why nephrology guidelines moved quickly to reflect it.

The guideline weight matters here. The KDIGO 2022 clinical-practice guideline — the international standard for kidney care in diabetes — elevated SGLT2 inhibitors to a first-line role for people with type 2 diabetes and CKD when kidney function permits, on the strength of exactly these trials.⁷ When a conservative guideline body makes a drug class foundational, the evidence behind it is not marginal.

Who they’re actually approved for — and who benefits

Strip away the excitement and the approved uses form a clear, evidence-anchored set. Depending on the specific drug and regulator, SGLT2 inhibitors are approved across three broad territories, and the population that benefits maps closely to the trials.

Type 2 diabetes. The original indication — glucose lowering — with the added, guideline-backed reason to reach for them preferentially in a diabetic who also has established cardiovascular disease, heart failure, or kidney disease.⁷

Heart failure, across the EF spectrum. This is the expansion that changed cardiology. Both empagliflozin and dapagliflozin carry heart-failure indications spanning reduced and preserved ejection fraction — and, critically, regardless of diabetes status. A non-diabetic with HFpEF is now a candidate, which would have sounded strange a decade ago.²³

Chronic kidney disease. Following DAPA-CKD and its empagliflozin counterpart, dapagliflozin is approved to slow CKD progression in appropriate patients — again, including non-diabetics — provided kidney filtration is above the trial thresholds.⁴

Who benefits most, then, is the person sitting in one of those trial populations: the diabetic with cardiorenal disease, the heart-failure patient of either EF type, the person with progressive CKD and protein in the urine. Who benefits least — and this is the crux of the hype problem — is the healthy person with none of these conditions, for whom no outcomes trial exists. For a broader map of where cardiometabolic drugs sit relative to lifestyle, our pharmaceuticals hub collects the same evidence-first treatment for the rest of the toolkit, and our companion read on PCSK9 inhibitors for cholesterol walks through the same relative-versus-absolute discipline in a neighboring class.

Safety: euglycemic DKA and genital infections

A drug this widely used has a well-characterized risk profile, and two items deserve to be stated plainly — which is why the safety claim lands at MODERATE: the risks are real and specific, not hand-waving, but they are manageable and generally uncommon rather than catastrophic.

Euglycemic diabetic ketoacidosis (DKA). DKA is a dangerous buildup of acidic ketones in the blood. Normally it announces itself with sky-high blood sugar, which is the warning sign clinicians watch for. The insidious thing about SGLT2 inhibitors is that they can trigger DKA while blood sugar stays near-normal — hence euglycemic (normal-glucose) DKA — because the drug is pulling glucose out through the urine and masking the usual alarm. It is uncommon, but it is the reason patients are often advised to pause these drugs around surgery, serious illness, fasting, or very-low-carbohydrate states, and to know the symptoms (nausea, vomiting, abdominal pain, deep breathing, confusion). This is a genuine, named hazard, not a theoretical one — it is recognized as a class effect in the mechanism and guideline literature.⁶⁷

Genital mycotic infections. The same glucosuria that drives the benefit also feeds yeast. Spilling sugar into the urine makes genital yeast infections (and, less often, urinary tract infections) more common, particularly in women and uncircumcised men. This is not a rare or theoretical signal: in EMPA-REG OUTCOME, genital infections occurred in 6.4 percent of empagliflozin patients versus 1.8 percent on placebo over roughly three years — higher in women than men.¹ Usually treatable and rarely serious, but common enough to be the most frequent reason people stop the drug. A rare but severe soft-tissue infection of the perineum (Fournier gangrene) has also been reported and carries a regulatory warning.

Rounding out the picture: a modest risk of volume depletion and low blood pressure (because of the diuretic effect), and attention to foot care given historical amputation signals with one drug in the class. None of this negates the benefit for the right patient — but it is exactly why these are prescription drugs under physician supervision, not something to self-start off a podcast recommendation.

Does it slow aging? The honest answer

Here is where the marketing gets ahead of the medicine, and it’s worth being precise. There is a legitimate scientific reason SGLT2 inhibitors attract geroscience interest. They touch several pathways that overlap with aging biology — a shift toward ketone metabolism, reduced inflammation, improved cellular energetics, less oxidative stress, and mild caloric loss through glucosuria (you are, after all, excreting calories). Those are the same levers longevity researchers care about, and animal and mechanistic work has made the class a plausible candidate worth studying. That interest is real and reasonable.

But interest is not proof, and this is the hard line. There is no randomized controlled trial showing that SGLT2 inhibitors extend lifespan or healthspan in healthy people. Every human outcome we have describes sick populations — heart failure, kidney disease, high-risk diabetes — where the drug prevents specific bad events. Extrapolating from “prevents heart-failure hospitalizations in patients with heart failure” to “makes a healthy person live longer” is a leap the data does not support. It might turn out to be true; it is exactly the kind of hypothesis that deserves a proper trial. Until that trial exists and reports, anyone selling these as a longevity pill for the well is trading on the drugs’ genuine cardiorenal success to make a claim the evidence hasn’t earned.

That is why the anti-aging claim earns a flat HYPE grade. Not because the idea is stupid — it’s scientifically interesting — but because in the specific form “proven anti-aging drug healthy people should take,” it is unsupported by any human longevity trial and layers a prescription drug’s real risks onto people who have none of the conditions it’s proven to treat.

What this article is not saying

This is not “SGLT2 inhibitors are overhyped drugs that don’t work.” The opposite. In heart failure and chronic kidney disease they are among the most important therapeutic advances of the last decade, replicated across multiple large randomized trials, and rightly written into cardiology and nephrology guidelines. For a person with HFpEF, or progressive CKD, or diabetes with cardiorenal disease, these drugs can genuinely change the trajectory of the illness. Dismissing them would be as wrong as overselling them.

This is not “SGLT2 inhibitors are a proven anti-aging pill.” That’s the HYPE claim, and it fails on the evidence. They are targeted cardiorenal and diabetes drugs with a defined risk profile, studied in and approved for specific sick populations — not a preventive supplement for healthy people, and not something whose longevity benefit has been demonstrated in any human trial. The very success that makes the real story compelling is being borrowed to sell a speculative one.

And this is not a treatment recommendation. Every figure here describes what published trials reported in defined populations, not what you should take. These are prescription drugs with real risks — euglycemic ketoacidosis and genital infections most notably — and a benefit that depends heavily on whether you actually have the conditions they treat. Whether one belongs in your regimen is a decision for you and a physician who knows your kidney function, your cardiac history, and your full medication list. The point of this piece is to show you what the trials prove and exactly where they stop, so that conversation can be an honest one. For a related look at how a repurposed prescription drug’s reputation can outrun its hard evidence, see our read on low-dose naltrexone.